COMMUNIQUÉS West-GlobeNewswire

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
01/06/2026
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
01/06/2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability in heavily [...]
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
01/06/2026
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Solid Biosciences to Participate at Upcoming Investor Conferences
01/06/2026
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
01/06/2026
Company is seeking partnerships for the most advanced long-acting depot injections in its pipeline, including Anastrozole Depot and Semaglutide Depot NESS ZIONA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd [...]
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
01/06/2026
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive [...]
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
01/06/2026
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics [...]
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
01/06/2026
- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, [...]
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
01/06/2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and [...]
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
01/06/2026
The company introduces an expanded on-premise and hybrid C5ISR suite that enables local AI processing, command automation, and response coordination for defense, security, and critical infrastructure NETANYA, Israel, [...]
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
01/06/2026
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure BOCA RATON, [...]
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
01/06/2026
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura [...]
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
01/06/2026
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs [...]
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
01/06/2026
If approved, D-PLEX 100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, [...]
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
01/06/2026
Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and FREIBURG, Germany, June 01, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland [...]
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
01/06/2026
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, [...]
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
01/06/2026
The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE [...]
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
01/06/2026
Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is expected to enter a [...]

Pages